Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 ...

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical

Related Keywords

United States ,United Kingdom ,Cambridge ,Cambridgeshire ,Dan Budwick ,Holly Manning ,Giuseppe Ciaramella ,Nasdaq ,Strategic Communications ,Beam Therapeutics Inc ,Exchange Commission ,Healthcare Products Regulatory Agency ,Private Securities Litigation Reform Act ,Annual Report ,